Pramlintide
Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects
AstraZeneca · Phase 2 · Completed · Enrollment 184
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Pramlintide acetate (AC137) | Obesity or overweight | n/r | n/r | n/r | n/r |